Targeting the NFκB signaling pathways for breast cancer prevention and therapy

Current Medicinal Chemistry

Volumn 22, Issue 2, 2015, Pages 264-289

  Wang, Wei ^a   Nag, Subhasree A ^a   Zhang, Ruiwen ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Breast cancer; Inflammation; Nf B; Transcription factor

Indexed keywords

ANDROGEN RECEPTOR; AROMATIC HYDROCARBON RECEPTOR; BETA ARRESTIN; CALMODULIN; CYCLIN DEPENDENT KINASE 2; CYCLIN E; DAXX PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; HEAT SHOCK PROTEIN 27; HISTONE DEACETYLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NOTCH1 RECEPTOR; PROTEASOME; PROTEIN C FOS; PROTEIN C JUN; PROTEIN MDM2; PROTEIN P53; S6 KINASE; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE 1; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR SP1; ANTINEOPLASTIC AGENT;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CELL CYCLE REGULATION; CHEMOSENSITIVITY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DNA REPAIR; HORMONE SENSITIVITY; HUMAN; INFLAMMATION; OXIDATIVE STRESS; PHENOTYPE; PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR INVASION; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; FEMALE; INFLAMMATORY BREAST NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; INFLAMMATORY BREAST NEOPLASMS; MOLECULAR TARGETED THERAPY; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84925445643     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666141106124315     Document Type: Article

References (349)

1. Shacter, E.; Weitzman, S. A. Chronic inflammation and cancer. Oncology (Williston Park), 2002, 16(2), 217-226, 229; discussion 230-232.
2. Grivennikov, S. I.; Greten, F. R.; Karin, M. Immunity, inflammation, and cancer. Cell, 2010, 140(6), 883-899.
3. Lu, H.; Ouyang, W.; Huang, C. Inflammation, a key event in cancer development. Mol. Cancer Res., 2006, 4(4), 221-233.
4. Balkwill, F.; Mantovani, A. Inflammation and cancer: back to Virchow? Lancet, 2001, 357(9255), 539-545.
5. Danese, S. Inflammatory bowel disease and inflammationassociated colon cancer: partners in crime. Curr. Drug Targets, 2008, 9(5), 360.
6. Erdman, S. E.; Poutahidis, T. Roles for inflammation and regulatory T cells in colon cancer. Toxicol. Pathol, 2010, 38(1), 76-87.
7. Terzic, J.; Grivennikov, S.; Karin, E.; Karin, M., Inflammation and colon cancer. Gastroenterology, 2010, 138(6), 2101-2114. e5.
8. Klampfer, L. Cytokines, inflammation and colon cancer. Curr. Cancer Drug Targets, 2011, 11(4), 451-464.
9. Carrasco, G.; Corvalan, A. H. Helicobacter pylori-Induced Chronic Gastritis and Assessing Risks for Gastric Cancer. Gastroenterol. Res. Pract., 2013, 2013, 393015.
10. Kong, Y.; Ma, L. Q.; Bai, P. S.; Da, R.; Sun, H.; Qi, X. G.; Ma, J. Q.; Zhao, R. M.; Chen, N. Z.; Nan, K. J. Helicobacter pylori promotes invasion and metastasis of gastric cancer cells through activation of AP-1 and up-regulation of CACUL1. Int. J. Biochem. Cell Biol., 2013, 45(11), 2666-2678.
11. Watanabe, T.; Takahashi, A.; Suzuki, K; Kurusu-Kanno, M.; Yamaguchi, K; Fujiki, H.; Suganuma, M. Epithelial-mesenchymal transition in human gastric cancer cell lines induced by TNF-alphainducing protein of Helicobacter pylori. Int. J. Cancer., 2014, 134(10), 2373-2382.
12. De Visser, K. E.; Korets, L. V.; Coussens, L. M. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer cell, 2005, 7(5), 411-423.
13. Meira, L. B.; Bugni, J. M.; Green, S. L.; Lee, C. W.; Pang, B.; Borenshtein, D.; Rickman, B. H.; Rogers, A. B.; Moroski-Erkul, C. A.; McFaline, J. L.; Schauer, D. B.; Dedon, P. C; Fox, J. G.; Samson, L. D. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J. Clin. Invest., 2008, 118(7), 2516-2525.
14. Niwa, T.; Ushijima, T. Induction of epigenetic alterations by chronic inflammation and its significance on carcinogenesis. Adv. Genet., 2010, 71, 41-56.
15. Zhang, M.; Zhou, S.; Zhang, L.; Ye, W.; Wen, Q.; Wang, J. Role of cancer-related inflammation in esophageal cancer., Crit. Rev. Eukaryot. Gene Expr., 2013, 23(1), 27-35.
16. Hamada, S.; Masamune, A.; Shimosegawa, T. Inflammation and pancreatic cancer: disease promoter and new therapeutic target. J. Gastroenterol., 2014, 49(4), 605-617.
17. Kwon, O. J.; Zhang, L.; Ittmann, M. M.; Xin, L. Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proc. Natl. Acad. Sci. USA., 2014, 111(5), E592-600.
18. Marshall, H. E.; Hess, D. T.; Stamler, J. S. S-nitrosylation: physiological regulation of NF-kappaB. Proc. Natl. Acad. Sci. USA, 2004, 101(24), 8841-8842.
19. Kawanishi, S.; Hiraku, Y.; Pinlaor, S.; Ma, N. Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol. Chem., 2006, 387(4), 365-372.
20. Hussain, S. P.; Hofseth, L. J.; Harris, C. C. Radical causes of cancer. Nat. Rev. Cancer, 2003, 3(4), 276-285.
21. Rayet, B.; Gelinas, C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene, 1999, 18(49), 6938-6947.
22. Ben-Neriah, Y.; Karin, M. Inflammation meets cancer, with NF-kB as the matchmaker. Nat Immunol, 2011, 12(8), 715-723.
23. Karin, M. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol, 2009, 1(5), a000141.
24. Perkins N. D. The diverse and complex roles of NF-kappaB subunits in cancer, Nat. Rev. Cancer, 2012, 12, 121-132.
25. Erstad, D. J.; Cusack Jr. J. C. Targeting the NFkB Pathway in Cancer Therapy, Surg. Oncol. Clin. N. Am., 2013, 22, 705-746.
26. Chaturvedi, M. M.; Sung, B.; Yadav, V. R.; Kannappan, R.; Aggarwal, B. B. NF-kappaB addiction and its role in cancer: 'one size does not fit all'. Oncogene, 2011, 30(14), 1615-1630.
27. Maeda, S.; Hikiba, Y.; Sakamoto, K.; Nakagawa, H.; Hirata, Y.; Hayakawa, Y.; Akanuma, M. Colon cancer-derived factors activate NF-kappaB in myeloid cells via TLR2 to link inflammation and tumorigenesis. Mol. Med. Rep., 2011, 4(6), 1083-1088.
28. Pikarsky, E.; Porat, R. M.; Stein, I.; Abramovitch, R.; Amit, S.; Kasem, S.; Gutkovich-Pyest, E.; Urieli-Shoval, S.; Galun, E.; Ben-Neriah, Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature, 2004, 431(7007), 461-466.
29. Setia, S.; Nehru, B.; Sanyal, S. N. Activation of NF-kappaB: Bridging the gap between inflammation and cancer in colitis-mediated colon carcinogenesis. Biomed. Pharmacother., 2014, 68(1), 119-128.
30. Ling J.; Kumar R. Crosstalk between NFkB and glucocorticoid signaling: a potential target of breast cancer therapy, Cancer Lett., 2012, 322, 119-126.
31. Sen, R.; Baltimore, D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell, 1986, 46(5), 705-716.
32. Ghosh, S.; May, M. J.; Kopp, E. B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Ann. Rev. Immunol, 1998, 16, 225-260.
33. Verma, I. M.; Stevenson, J. K.; Schwarz, E. M.; Van Antwerp, D.; Miyamoto, S. Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes. Dev., 1995, 9(22), 2723-2735.
34. Lin, L.; Ghosh, S. A glycine-rich region in NF-kappaB p105 functions as a processing signal for the generation of the p50 subunit. Mol. Cell Biol, 1996, 16(5), 2248-2254.
35. Baeuerle, P. A.; Baltimore, D. I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science, 1988, 242(4878), 540-546.
36. Gupta, S. C; Kim, J. H.; Prasad, S.; Aggarwal, B. B. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metas. Rev., 2010, 29(3), 405-434.
37. Gilmore, T. D. Multiple myeloma: lusting for NF-kappaB. Cancer cell 2007, 12(2), 95-97.
38. Wu, J. T.; Kral, J. G. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J. Surg. Res., 2005, 123(1), 158-169.
39. Romieu-Mourez, R.; Kim, D. W.; Shin, S. M.; Demicco, E. G.; Landesman-Bollag, E.; Seldin, D. C; Cardiff, R. D.; Sonenshein, G. E. Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors. Mol. Cell Biol, 2003, 23(16), 5738-5754.
40. Liu, M.; Sakamaki, T.; Casimiro, M. C; Willmarth, N. E.; Quong, A. A.; Ju, X.; Ojeifo, J.; Jiao, X.; Yeow, W. S.; Katiyar, S.; Shirley, L. A.; Joyce, D.; Lisanti, M. P.; Albanese, C; Pestell, R. G. The canonical NF-kappaB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. Cancer Res., 2010, 70(24), 10464-10473.
41. Boehm, J. S.; Zhao, J. J.; Yao, J.; Kim, S. Y.; Firestein, R.; Dunn, I. F.; Sjostrom, S. K.; Garraway, L. A.; Weremowicz, S.; Richardson, A. L.; Greulich, H.; Stewart, C. J.; Mulvey, L. A.; Shen, R. R.; Ambrogio, L.; Hirozane-Kishikawa, T.; Hill, D. E.; Vidal, M.; Meyerson, M.; Grenier, J. K.; Hinkle, G.; Root, D. E.; Roberts, T. M.; Lander, E. S.; Polyak, K.; Hahn, W. C. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell, 2007, 129(6), 1065-1079.
42. Huber, M. A.; Azoitei, N.; Baumann, B.; Grunert, S.; Sommer, A.; Pehamberger, H.; Kraut, N.; Beug, H.; Wirth, T. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J. Clin. Invest., 2004, 114(4), 569-581.
43. Karin, M.; Cao, Y.; Greten, F. R.; Li, Z. W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer, 2002, 2(4), 301-310.
44. Di Donato, J. A.; Mercurio, F.; Karin, M. NF-kappaB and the link between inflammation and cancer. Immunol Rev., 2012, 246(1), 379-400.
45. Cabannes, E.; Khan, G.; Aillet, F.; Jarrett, R. F.; Hay, R. T. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. Oncogene, 1999, 18, 3063-3070.
46. Pacifico, F.; Leonardi, A. NF-kappaB in solid tumors. Biochem. Pharmacol, 2006, 72(9), 1142-1152.
47. Dos Santos, N. R.; Ghezzo, M. N.; R. C. Da Silva, Fernandes, M. T. NFkB in T-cell Acute Lymphoblastic Leukemia: Oncogenic Functions in Leukemic and in Microenvironmental Cells, Cancers (Basel), 2010, 2, 1838-1860.
48. Pavan, A.; Spina, M.; Canzonieri, V.; Sansonno, S.; Toffoli, G.; De Re V. Recent prognostic factors in diffuse large B-cell lymphoma indicate NF-kappaB pathway as a target for new therapeutic strategies, Leuk. Lymphoma, 2008, 49, 2048-2058.
49. Gilmore, T. D.; Gerondakis, S.; The c-Rel Transcription Factor in Development and Disease, Genes Cancer, 2011, 2, 695-611.
50. Mathas, S.; Johrens, K.; Joos, S.; Lietz, A.; Hummel, F.; Janz, M.; Jundt, F.; Anagnostopoulos, I.; Bommert, K.; Lichter, P.; Stein, H.; Scheidereit, C.; Dorken, B. Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic largecell, and other peripheral T-cell lymphomas, Blood, 2005, 106, 4287-4293.
51. Neri, A.; Chang, C. C.; Lombardi, L.; Salina, M.; Corradini, P.; Maiolo, A. T.; Chaganti, R. S.; Dalla-Favera, R. B cell lymphomaassociated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50, Cell, 1991, 67, 1075-1087.
52. Liptay, S.; Schmid, R. M.; Perkins, N. D.; Meltzer, P.; Altherr, M. R.; McPherson, J. D.; Wasmuth, J. J.; G. J. Nabel, Related subunits of NF-kappa B map to two distinct loci associated with translocations in leukemia, NFKB1 and NFKB2, Genomics, 1992, 13, 287-292.
53. Keats, J. J.; Fonseca, R.; Chesi, M.; Schop, R.; Baker, A.; W. J. Chng, S. Van Wier, R. Tiedemann, C. X. Shi, M. Sebag, E. Braggio, T. Henry, Y. X. Zhu, H. Fogle, T. Price-Troska, G. Ahmann, C. Mancini, L. A. Brents, S. Kumar, P. Greipp, A. Dispenzieri, B. Bryant, G. Mulligan, L. Bruhn, M. Barrett, R. Valdez, J. Trent, A. K. Stewart, J. Carpten, P. L. Bergsagel, Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma, Cancer cell, 2007, 12, 131-144.
54. Hamdane, M.; David-Cordonnier, M. H.; D'Halluin, J. C. Activation of p65 NF-kappaB protein by p210BCR-ABL in a myeloid cell line (P210BCR-ABL activates p65 NF-kappaB). Oncogene, 1997, 15(19), 2267-2275.
55. Stirewalt, D. L.; Meshinchi, S.; Radich, J. P. Molecular targets in acute myelogenous leukemia. Blood Rev., 2003, 17(1), 15-23.
56. Molinolo, A. A.; Amornphimoltham, P.; Squarize, C. H.; Castilho, R. M.; Patel, V.; Gutkind, J. S. Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol., 2009, 45(4-5), 324-334.
57. Annunziata, C. M.; Stavnes, H. T.; Kleinberg, L.; Berner, A.; Hernandez, L. F.; Birrer, M. J.; Steinberg, S. M.; Davidson, B.; Kohn, E. C. Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer, 2010, 116(13), 3276-3284.
58. Alberti, C.; Pinciroli, P.; Valeri, B.; Ferri, R.; Ditto, A.; Umezawa, K.; Sensi, M.; Canevari, S.; Tomassetti, A. Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer. Oncogene, 2012, 31(37), 4139-4149.
59. Guo, R. X.; Qiao, Y. H.; Zhou, Y.; Li, L. X.; Shi, H. R.; Chen, K. S. Increased staining for phosphorylated AKT and nuclear factorkappaB p65 and their relationship with prognosis in epithelial ovarian cancer. Pathol. Int., 2008, 58(12), 749-756.
60. Fujioka, S.; Sclabas, G. M.; Schmidt, C.; Frederick, W. A.; Dong, Q. G.; Abbruzzese, J. L.; Evans, D. B.; Baker, C.; Chiao, P. J. Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin. Cancer Res., 2003, 9(1), 346-354.
61. Wilson, W. 3rd; Baldwin, A. S. Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer. Cancer Res., 2008, 68(19), 8156-8163.
62. Gasparian, A. V.; Yao, Y. J.; Kowalczyk, D.; Lyakh, L. A.; Karseladze, A.; Slaga, T. J.; Budunova, I. V. The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J. Cell Sci., 2002, 115(Pt 1), 141-151.
63. Brantley, D. M.; Yull, F. E.; Muraoka, R. S.; Hicks, D. J.; Cook, C. M.; Kerr, L. D. Dynamic expression and activity of NF-kappaB during post-natal mammary gland morphogenesis. Mech. Dev., 2000, 97(1-2), 149-155.
64. Brantley, D. M.; Chen, C. L.; Muraoka, R. S.; Bushdid, P. B.; Bradberry, J. L.; Kittrell, F.; Medina, D.; Matrisian, L. M.; Kerr, L. D.; Yull, F. E. Nuclear factor-kappaB (NF-kappaB) regulates proliferation and branching in mouse mammary epithelium. Mol. Biol. Cell., 2001, 12(5), 1445-1455.
65. Cogswell, P. C.; Guttridge, D. C.; Funkhouser, W. K.; Baldwin, A. S., Jr. Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene, 2000, 19(9), 1123-1131.
66. Nakshatri, H.; Bhat-Nakshatri, P.; Martin, D. A.; Goulet, R. J., Jr.; Sledge, G. W., Jr. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol. Cell Biol., 1997, 17(7), 3629-3639.
67. Sovak, M. A.; Bellas, R. E.; Kim, D. W.; Zanieski, G. J.; Rogers, A. E.; Traish, A. M.; Sonenshein, G. E. Aberrant nuclear factorkappaB/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest., 1997, 100(12), 2952-2960.
68. Demicco, E. G.; Kavanagh, K. T.; Romieu-Mourez, R.; Wang, X.; Shin, S. R.; Landesman-Bollag, E.; Seldin, D. C; Sonenshein, G. E. RelB/p52 NF-kappaB complexes rescue an early delay in mammary gland development in transgenic mice with targeted superrepressor IkappaB-alpha expression and promote carcinogenesis of the mammary gland. Mol. Cell Biol, 2005, 25(22), 10136-10147.
69. Srivastava, S.; Matsuda, M.; Hou, Z.; Bailey, J. P.; Kitazawa, R.; Herbst, M. P.; Horseman, N. D. Receptor activator of NF-kappaB ligand induction via Jak2 and Stat5a in mammary epithelial cells. J. Biol. Chem., 2003, 278(46), 46171-46178.
70. Van Laere, S. J.; Van Der Auwera, I.; Van Den Eynden, G. G.; Elst, H. J.; Weyler, J.; Harris, A. L.; Van Dam, P.; Van Marck, E. A.; Vermeulen, P. B.; Dirix, L. Y. Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. Clin. Cancer Res., 2006, 12(11 Pt 1), 3249-3256.
71. Van Laere, S. J.; Van Der Auwera, I.; Van Den Eynden, G. G.; Van Dam, P.; Van Marck, E. A.; Vermeulen, P. B.; Dirix, L. Y. NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation. Br. J. Cancer, 2007, 97(5), 659-669.
72. Romagnoli, M.; Belguise, K.; Yu, Z.; Wang, X.; Landesman-Bollag, E.; Seldin, D. C; Chalbos, D.; Barille-Nion, S.; Jezequel, P.; Seldin, M. L.; Sonenshein, G. E. Epithelial-to-mesenchymal transition induced by TGF-beta1 is mediated by Blimp-1-dependent repression of BMP-5. Cancer Res., 2012, 72(23), 6268-6278.
73. Shostak, K.; Chariot, A. NF-kappaB, stem cells and breast cancer: the links get stronger. Breast Cancer Res., 2011, 13(4), 214.
74. Yu, H.; Mohan, S.; Natarajan, M. Radiation-Triggered NF-kappaB Activation is Responsible for the Angiogenic Signaling Pathway and Neovascularization for Breast Cancer Cell Proliferation and Growth. Breast Cancer Res., 2012, 6, 125-135.
75. Zhou, Y.; Eppenberger-Castori, S.; Eppenberger, U.; Benz, C. C. The NFkappaB pathway and endocrine-resistant breast cancer. Endocr. Relat. Cancer, 2005, 12 Suppl 1, S37-46.
76. Tobar, N.; Villar, V.; Santibanez, J. F. ROS-NFkappaB mediates TGF-beta1-induced expression of urokinase-type plasminogen activator, matrix metalloproteinase-9 and cell invasion. Mol. Cell Biochem., 2010, 340(1-2), 195-202.
77. Oeckinghaus, A.; Ghosh, S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb. Perspect. Biol, 2009, 1(4), a000034.
78. Pahl, H. L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene, 1999, 18(49), 6853-6866.
79. Pujari, R.; Hunte, R.; Khan, W. N.; Shembade, N. A20-mediated negative regulation of canonical NF-kB signaling pathway. Immunol. Res., 2013, 57(1-3), 166-171.
80. Sun, S. C. Non-canonical NF-kappaB signaling pathway. Cell Res., 2011, 21(1), 71-85.
81. Razani, B.; Reichardt, A. D.; Cheng, G. Non-canonical NF-kappaB signaling activation and regulation: principles and perspectives. Immunol. Rev., 2011, 244(1), 44-54.
82. Kendellen, M. F.; Bradford, J. W.; Lawrence, C. L.; Clark, K. S.; Baldwin, A. S. Canonical and non-canonical NF-kappaB signaling promotes breast cancer tumor-initiating cells. Oncogene, 2014, 33(10), 1297-1305.
83. Huang, T. T.; Wuerzberger-Davis, S. M.; Wu, Z. H.; Miyamoto, S. Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress. Cell, 2003, 115(5), 565-576.
84. Kato, T., Jr.; Delhase, M.; Hoffmann, A.; Karin, M. CK2 Is a C-Terminal IkappaB Kinase Responsible for NF-kappaB Activation during the UV Response. Mol. Cell, 2003, 12(4), 829-839.
85. Tergaonkar, V.; Bottero, V.; Ikawa, M.; Li, Q.; Verma, I. M. IkappaB kinase-independent IkappaBalpha degradation pathway: functional NF-kappaB activity and implications for cancer therapy. Mol. Cell Biol., 2003, 23(22), 8070-8083.
86. Tieri, P.; Termanini, A.; Bellavista, E.; Salvioli, S.; Capri, M.; Franceschi, C. Charting the NF-kappaB pathway interactome map. PloS one, 2012, 7(3), e32678.
87. Huang, B.; Yang, X. D.; Lamb, A.; Chen, L. F. Posttranslational modifications of NF-kappaB: another layer of regulation for NF-kappaB signaling pathway. Cell Signal., 2010, 22(9), 1282-1290.
88. Liu, Y.; Smith, P. W.; Jones, D. R. Breast cancer metastasis suppressor 1 functions as a corepressor by enhancing histone deacetylase 1-mediated deacetylation of RelA/p65 and promoting apoptosis. Mol. Cell Biol., 2006, 26(23), 8683-8696.
89. Yde, C. W.; Emdal, K. B.; Guerra, B.; Lykkesfeldt, A. E. NFkappaB signaling is important for growth of antiestrogen resistant breast cancer cells. Breast Cancer Res. Treat., 2012, 135(1), 67-78.
90. Perkins, N. D. Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene, 2006, 25(51), 6717-6730.
91. Mukhopadhyay, N. K.; Ferdinand, A. S.; Mukhopadhyay, L.; Cinar, B.; Lutchman, M.; Richie, J. P.; Freeman, M. R.; Liu, B. C. Unraveling androgen receptor interactomes by an array-based method: discovery of proto-oncoprotein c-Rel as a negative regulator of androgen receptor. Exp. Cell Res., 2006, 312(19), 3782-3795.
92. Vogel, C. F.; Sciullo, E.; Li, W.; Wong, P.; Lazennec, G.; Matsumura, F. RelB, a new partner of aryl hydrocarbon receptormediated transcription. Mol. Endocrinol., 2007, 21(12), 2941-2955.
93. Gao, H.; Sun, Y.; Wu, Y.; Luan, B.; Wang, Y.; Qu, B.; Pei, G. Identification of beta-arrestin2 as a G protein-coupled receptorstimulated regulator of NF-kappaB pathways. Mol. Cell, 2004, 14(3), 303-317.
94. Parameswaran, N.; Pao, C. S.; Leonhard, K. S.; Kang, D. S.; Kratz, M.; Ley, S. C.; Benovic, J. L. Arrestin-2 and G protein-coupled receptor kinase 5 interact with NFkappaB1 p105 and negatively regulate lipopolysaccharide-stimulated ERK1/2 activation in macrophages. J. Biol. Chem., 2006, 281(45), 34159-34170.
95. Kroll, M.; Margottin, F.; Kohl, A.; Renard, P.; Durand, H.; Concordet, J. P.; Bachelerie, F.; Arenzana-Seisdedos, F.; Benarous, R. Inducible degradation of IkappaBalpha by the proteasome requires interaction with the F-box protein h-betaTrCP. J. Biol. Chem., 1999, 274(12), 7941-7945.
96. Khan, N.; Rahim, S. S.; Boddupalli, C. S.; Ghousunnissa, S.; Padma, S.; Pathak, N.; Thiagarajan, D.; Hasnain, S. E.; Mukhopadhyay, S. Hydrogen peroxide inhibits IL-12 p40 induction in macrophages by inhibiting c-rel translocation to the nucleus through activation of calmodulin protein. Blood, 2006, 107(4), 1513-1520.
97. Chen, E.; Li, C. C. Association of Cdk2/cyclin E and NF-kappa B complexes at G1/S phase. Biochem. Biophys. Res. Comm., 1998, 249(3), 728-734.
98. Stein, B.; Baldwin, A. S., Jr.; Ballard, D. W.; Greene, W. C.; Angel, P.; Herrlich, P. Cross-coupling of the NF-kappa B p65 and Fos/Jun. transcription factors produces potentiated biological function. EMBO J., 1993, 12(10), 3879-3891.
99. Shifera, A. S.; Friedman, J. M.; Horwitz, M. S. IKK gamma (NEMO) is involved in the coordination of the AP-1 and NF-kappa B pathways. Mol. Cell Biol., 2008, 310(1-2), 181-190.
100. Wang, D.; Westerheide, S. D.; Hanson, J. L.; Baldwin, A. S., Jr. Tumor necrosis factor alpha-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II. J. Biol. Chem., 2000, 275(42), 32592-32597.
101. Bijli, K. M.; Minhajuddin, M.; Fazal, F.; O'Reilly, M. A.; Platanias, L. C.; Rahman, A. c-Src interacts with and phosphorylates RelA/p65 to promote thrombin-induced ICAM-1 expression in endothelial cells. Am. J. Physiol. Lung Cell Mol. Physiol., 2007, 292(2), L396-404.
102. Park, J.; Lee, J. H.; La, M.; Jang, M. J.; Chae, G. W.; Kim, S. B.; Tak, H.; Jung, Y.; Byun, B.; Ahn, J. K.; Joe, C. O. Inhibition of NF-kappaB acetylation and its transcriptional activity by Daxx. J. Mol. Biol,. 2007, 368(2), 388-397.
103. Lim, C. A.; Yao, F.; Wong, J. J.; George, J.; Xu, H.; Chiu, K. P.; Sung, W. K.; Lipovich, L.; Vega, V. B.; Chen, J.; Shahab, A.; Zhao, X. D.; Hibberd, M.; Wei, C. L.; Lim, B.; Ng, H. H.; Ruan, Y.; Chin, K. C. Genome-wide mapping of RELA (p65) binding identifies E2F1 as a transcriptional activator recruited by NF-kappaB upon TLR4 activation. Mol. Cell, 2007, 27(4), 622-635.
104. Lee, S. T.; Li, Z.; Wu, Z.; Aau, M.; Guan, P.; Karuturi, R. K.; Liou, Y. C.; Yu, Q. Context-specific regulation of NF-kappaB target gene expression by EZH2 in breast cancers. Mol. Cell, 2011, 43(5), 798-810.
105. Quaedackers, M. E.; Van Den Brink, C. E.; Van Der Saag, P. T.; Tertoolen, L. G. Direct interaction between estrogen receptor alpha and NF-kappaB in the nucleus of living cells. Mol. Cell Endocrinol., 2007, 273(1-2), 42-50.
106. Feldman, I.; Feldman, G. M.; Mobarak, C.; Dunkelberg, J. C.; Leslie, K. K. Identification of proteins within the nuclear factorkappa B transcriptional complex including estrogen receptor-alpha. Am. J. Obstet. Gynecol., 2007, 196(4), 394 e1-11; discussion 394 e11-3.
107. Kalaitzidis, D.; Gilmore, T. D. Transcription factor cross-talk: the estrogen receptor and NF-kappaB. Trend Endocrinol. Metabol., 2005, 16(2), 46-52.
108. Higashitsuji, H.; Liu, Y.; Masuda, T.; Fujita, T.; Abdel-Aziz, H. I.; Kongkham, S.; Dawson, S.; John Mayer, R.; Itoh, Y.; Sakurai, T.; Itoh, K.; Fujita, J. The oncoprotein gankyrin interacts with RelA and suppresses NF-kappaB activity. Biochem. Biophys. Res. Comm., 2007, 363(3), 879-884.
109. Kammanadiminti, S. J.; Chadee, K. Suppression of NF-kappaB activation by Entamoeba histolytica in intestinal epithelial cells is mediated by heat shock protein 27. J. Biol. Chem., 2006, 281(36), 26112-26120.
110. Ashburner, B. P.; Westerheide, S. D.; Baldwin, A. S., Jr. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol. Cell Biol., 2001, 21(20), 7065-7077.
111. Viatour, P.; Legrand-Poels, S.; Van Lint, C.; Warnier, M.; Merville, M. P.; Gielen, J.; Piette, J.; Bours, V.; Chariot, A. Cytoplasmic IkappaBalpha increases NF-kappaB-independent transcription through binding to histone deacetylase (HDAC) 1 and HDAC3. J. Biol. Chem., 2003, 278(47), 46541-46548.
112. Chen, L.; Fischle, W.; Verdin, E.; Greene, W. C. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science, 2001, 293(5535), 1653-1657.
113. Liu, S.; Wu, L. C.; Pang, J.; Santhanam, R.; Schwind, S.; Wu, Y. Z.; Hickey, C. J.; Yu, J.; Becker, H.; Maharry, K.; Radmacher, M. D.; Li, C.; Whitman, S. P.; Mishra, A.; Stauffer, N.; Eiring, A. M.; Briesewitz, R.; Baiocchi, R. A.; Chan, K. K.; Paschka, P.; Caligiuri, M. A.; Byrd, J. C.; Croce, C. M.; Bloomfield, C. D.; Perrotti, D.; Garzon, R.; Marcucci, G. Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell, 2010, 17(4), 333-347.
114. Meyer, C. F.; Wang, X.; Chang, C.; Templeton, D.; Tan, T. H. Interaction between c-Rel and the mitogen-activated protein kinase kinase kinase 1 signaling cascade in mediating kappaB enhancer activation. J. Biol. Chem., 1996, 271(15), 8971-8976.
115. Dan, H. C.; Cooper, M. J.; Cogswell, P. C.; Duncan, J. A.; Ting, J. P.; Baldwin, A. S. Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev., 2008, 22(11), 1490-1500.
116. Pham, L. V.; Tamayo, A. T.; Yoshimura, L. C.; Lin-Lee, Y. C.; Ford, R. J. Constitutive NF-kappaB and NFAT activation in aggressive B-cell lymphomas synergistically activates the CD154 gene and maintains lymphoma cell survival. Blood, 2005, 106(12), 3940-3947.
117. Song, L. L.; Peng, Y.; Yun, J.; Rizzo, P.; Chaturvedi, V.; Weijzen, S.; Kast, W. M.; Stone, P. J.; Santos, L.; Loredo, A.; Lendahl, U.; Sonenshein, G.; Osborne, B.; Qin, J. Z.; Pannuti, A.; Nickoloff, B. J.; Miele, L. Notch-1 associates with IKKalpha and regulates IKK activity in cervical cancer cells. Oncogene, 2008, 27(44), 5833-5844.
118. Kitamura, T.; Sekimata, M.; Kikuchi, S.; Homma, Y. Involvement of poly (ADP-ribose) polymerase 1 in ERBB2 expression in rheumatoid synovial cells. Am. J. Physiol. Cell Physiol., 2005, 289(1), C82-88.
119. Kalkhoven, E.; Wissink, S.; Van Der Saag, P. T.; Van Der Burg, B. Negative interaction between the RelA (p65) subunit of NF-kappaB and the progesterone receptor. J. Biol. Chem., 1996, 271(11), 6217-6224.
120. Nourbakhsh, M.; Hauser, H. Constitutive silencing of IFN-beta promoter is mediated by NRF (NF-kappaB-repressing factor), a nuclear inhibitor of NF-kappaB. EMBO J., 1999, 18(22), 6415-6425.
121. Wu, W. S.; Xu, Z. X.; Hittelman, W. N.; Salomoni, P.; Pandolfi, P. P.; Chang, K. S. Promyelocytic leukemia protein sensitizes tumor necrosis factor alpha-induced apoptosis by inhibiting the NF-kappaB survival pathway. J. Biol. Chem., 2003, 278(14), 12294-12304.
122. Von Brandenstein, M. G.; Ngum Abety, A.; Depping, R.; Roth, T.; Koehler, M.; Dienes, H. P.; Fries, J. W. A p38-p65 transcription complex induced by endothelin-1 mediates signal transduction in cancer cells. Biochim. Biophys. Acta, 2008, 1783(9), 1613-1622.
123. Chang, N. S. The non-ankyrin C terminus of Ikappa Balpha physically interacts with p53 in vivo and dissociates in response to apoptotic stress, hypoxia, DNA damage, and transforming growth factor-beta 1-mediated growth suppression. J. Biol. Chem., 2002, 277(12), 10323-10331.
124. Wan, F.; Anderson, D. E.; Barnitz, R. A.; Snow, A.; Bidere, N.; Zheng, L.; Hegde, V.; Lam, L. T.; Staudt, L. M.; Levens, D.; Deutsch, W. A.; Lenardo, M. J. Ribosomal protein S3: a KH domain subunit in NF-kappaB complexes that mediates selective gene regulation. Cell, 2007, 131(5), 927-939.
125. Rual, J. F.; Venkatesan, K.; Hao, T.; Hirozane-Kishikawa, T.; Dricot, A.; Li, N.; Berriz, G. F.; Gibbons, F. D.; Dreze, M.; Ayivi-Guedehoussou, N.; Klitgord, N.; Simon, C.; Boxem, M.; Milstein, S.; Rosenberg, J.; Goldberg, D. S.; Zhang, L. V.; Wong, S. L.; Franklin, G.; Li, S.; Albala, J. S.; Lim, J.; Fraughton, C.; Llamosas, E.; Cevik, S.; Bex, C.; Lamesch, P.; Sikorski, R. S.; Vandenhaute, J.; Zoghbi, H. Y.; Smolyar, A.; Bosak, S.; Sequerra, R.; Doucette-Stamm, L.; Cusick, M. E.; Hill, D. E.; Roth, F. P.; Vidal, M. Towards a proteome-scale map of the human protein-protein interaction network. Nature, 2005, 437(7062), 1173-1178.
126. Hirano, F.; Tanaka, H.; Hirano, Y.; Hiramoto, M.; Handa, H.; Makino, I.; Scheidereit, C. Functional interference of Sp1 and NF-kappaB through the same DNA binding site. Mol. Cell Biol., 1998, 18(3), 1266-1274.
127. Yu, Z.; Zhang, W.; Kone, B. C. Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor kappaB. Biochem J., 2002, 367(Pt 1), 97-105.
128. Yoshida, Y.; Kumar, A.; Koyama, Y.; Peng, H.; Arman, A.; Boch, J. A.; Auron, P. E. Interleukin 1 activates STAT3/nuclear factorkappaB cross-talk via a unique TRAF6- and p65-dependent mechanism. J. Biol. Chem., 2004, 279(3), 1768-1776.
129. Chung, S. S.; Aroh, C.; Vadgama, J. V. Constitutive activation of STAT3 signaling regulates hTERT and promotes stem cell-like traits in human breast cancer cells. PloS one, 2013, 8(12), e83971.
130. Desantis, C.; Ma, J.; Bryan, L.; Jemal, A. Breast cancer statistics, 2013. CA: Cancer J. Clin., 2013. 64(2014), 52-62.
131. Williams, C.; Lin, C. Y. Oestrogen receptors in breast cancer: basic mechanisms and clinical implications. Ecancermedicalscience, 2013, 7, 370.
132. Yue, W.; Yager, J. D.; Wang, J. P.; Jupe, E. R.; Santen, R. J. Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis. Steroids, 2013, 78(2), 161-170.
133. Yager, J. D.; Davidson, N. E. Estrogen carcinogenesis in breast cancer. N. Eng. J. Med., 2006, 354(3), 270-282.
134. Simstein, R.; Burow, M.; Parker, A.; Weldon, C.; Beckman, B. Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp. Biol. Med. (Maywood), 2003, 228(9), 995-1003.
135. D'Abreo, N.; Hindenburg, A. A. Sex hormone receptors in breast cancer. Vitam. Horm., 2013, 93, 99-133.
136. Toy, W.; Shen, Y.; Won, H.; Green, B.; Sakr, R. A.; Will, M.; Li, Z.; Gala, K.; Fanning, S.; King, T. A.; Hudis, C.; Chen, D.; Taran, T.; Hortobagyi, G.; Greene, G.; Berger, M.; Baselga, J.; Chandarlapaty, S. ESR1 ligand-binding domain mutations in hormoneresistant breast cancer. Nature genetics, 2013, 45(12), 1439-1445.
137. Cristofanilli, M.; Singletary, E. S.; Hortobagyi, G. N. Inflammatory breast carcinoma: the sphinx of breast cancer research. J. Clin. Oncol., 2004, 22(2), 381-383; author reply 383.
138. Peddi, P. F.; Ellis, M. J.; Ma, C. Molecular basis of triple negative breast cancer and implications for therapy. Int. J. Breast Cancer, 2012, 2012, 217185.
139. Sarkar, D. K.; Jana, D.; Patil, P. S.; Chaudhari, K. S.; Chattopadhyay, B. K.; Chikkala, B. R.; Mandal, S.; Chowdhary, P. Role of NFkB as a Prognostic Marker in Breast Cancer: A Pilot Study in Indian Patients. Indian J. Surg. Oncol, 2013, 4, 242-247.
140. Yamaguchi, N.; Ito, T.; Azuma, S.; Ito, E.; Honma, R.; Yanagisawa, Y.; Nishikawa, A.; Kawamura, M.; Imai, J.; Watanabe, S.; Semba, K.; Inoue, J. Constitutive activation of nuclear factorkappaB is preferentially involved in the proliferation of basal-like subtype breast cancer cell lines. Cancer Sci., 2009, 100(9), 1668-1674.
141. Gilmore, T. D. The Re1/NF-kappa B/I kappa B signal transduction pathway and cancer. Cancer Treat. Res., 2003, 115, 241-265.
142. Baldwin, A. S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J. Clin. Invest., 2001, 107(3), 241-246.
143. Zhou, A. Y.; Shen, R. R.; Kim, E.; Lock, Y. J.; Xu, M.; Chen, Z. J.; Hahn, W. C. IKKepsilon-mediated tumorigenesis requires K63-linked polyubiquitination by a cIAP1/cIAP2/TRAF2 E3 ubiquitin ligase complex. Cell Rep., 2013, 3(3), 724-733.
144. Shen, R. R.; Hahn, W. C. Emerging roles for the non-canonical IKKs in cancer. Oncogene, 2011, 30(6), 631-641.
145. Hagemann, T.; Biswas, S. K.; Lawrence, T.; Sica, A.; Lewis, C. E. Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB. Blood, 2009, 113(14), 3139-3146.
146. Smyth, M. J.; Dunn, G. P.; Schreiber, R. D. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol, 2006, 90, 1-50.
147. Dunn, G. P.; Old, L. J.; Schreiber, R. D. The three Es of cancer immunoediting. Ann. Rev. Immunol, 2004, 22, 329-360.
148. De Nardo, D. G.; Coussens, L. M. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res., 2007, 9(4), 212.
149. Roy, L. D.; Curry, J. M.; Sahraei, M.; Besmer, D. M.; Kidiyoor, A.; Gruber, H. E.; Mukherjee, P. Arthritis augments breast cancer metastasis: role of mast cells and SCF/c-Kit signaling. Breast Cancer Res., 2013, 15(2), R32.
150. Stewart, T.; Tsai, S. C; Grayson, H.; Henderson, R.; Opelz, G. Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet, 1995, 346(8978), 796-798.
151. Okoh, V.; Deoraj, A.; Roy, D. Estrogen-induced reactive oxygen species-mediated signalings contribute to breast cancer. Biochim. Biophys. Acta, 2011, 1815(1), 115-133.
152. Hinz, M.; Krappmann, D.; Eichten, A.; Heder, A.; Scheidereit, C; Strauss, M. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol, 1999, 19(4), 2690-2698.
153. Perkins, N. D.; Felzien, L. K.; Betts, J. C; Leung, K.; Beach, D. H.; Nabel, G. J. Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator. Science, 1997, 275(5299), 523-527.
154. Kim, D. W.; Gazourian, L.; Quadri, S. A.; Romieu-Mourez, R.; Sherr, D. H.; Sonenshein, G. E. The RelA NF-kappaB subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells. Oncogene, 2000, 19(48), 5498-5506.
155. Biswas, D. K.; Cruz, A. P.; Gansberger, E.; Pardee, A. B. Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc. Natl. Acad. Sci. U S A, 2000, 97(15), 8542-8547.
156. Neil, J. R.; Tian, M.; Schiemann, W. P. X-linked inhibitor of apoptosis protein and its E3 ligase activity promote transforming growth factor-{beta}-mediated nuclear factor-{kappa} B activation during breast cancer progression. J. Biol. Chem., 2009, 284(32), 21209-21217.
157. Wang, C. Y.; Mayo, M. W.; Korneluk, R. G.; Goeddel, D. V.; Baldwin, A. S., Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science, 1998, 281(5383), 1680-1683.
158. Nanda, D. P.; Sil, H.; Moulik, S.; Biswas, J.; Mandal, S. S.; Chatterjee, A. Matrix metalloproteinase-9 as a potential tumor marker in breast cancer. J. Environ. Pathol. Toxicol, 2013, 32(2), 115-129.
159. Bist, P.; Leow, S. C; Phua, Q. H.; Shu, S.; Zhuang, Q.; Loh, W. T.; Nguyen, T. H.; Zhou, J. B.; Hooi, S. C; Lim, L. H. Annexin-1 interacts with NEMO and RIP1 to constitutively activate IKK complex and NF-kappaB: implication in breast cancer metastasis. Oncogene, 2011, 30(28), 3174-3185.
160. Sliva, D.; Rizzo, M. T.; English, D. Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator. J. Biol. Chem., 2002, 277(5), 3150-3157.
161. Chavey, C; Muhlbauer, M.; Bossard, C; Freund, A.; Durand, S.; Jorgensen, C; Jobin, C; Lazennec, G. Interleukin-8 expression is regulated by histone deacetylases through the nuclear factorkappaB pathway in breast cancer. Mol. Pharmacol, 2008, 74(5), 1359-1366.
162. Chen, Q.; Massague, J. Molecular pathways: VCAM-1 as a potential therapeutic target in metastasis. Clin. Cancer Res., 2012, 18(20), 5520-5525.
163. Helbig, G.; Christopherson, K. W., 2nd; Bhat-Nakshatri, P.; Kumar, S.; Kishimoto, H.; Miller, K. D.; Broxmeyer, H. E.; Nakshatri, H. NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J. Biol. Chem., 2003, 278(24), 21631-21638.
164. Farina, A. R.; Cappabianca, L.; De Santis, G.; Di Ianni, N.; Ruggeri, P.; Ragone, M.; Merolle, S.; Tonissen, K. F.; Gulino, A.; Mackay, A. R. Thioredoxin stimulates MMP-9 expression, de-regulates the MMP-9/TIMP-1 equilibrium and promotes MMP-9 dependent invasion in human MDA-MB-231 breast cancer cells. FEBS Lett., 2011, 585(20), 3328-3336.
165. Chua, H. L.; Bhat-Nakshatri, P.; Clare, S. E.; Morimiya, A.; Badve, S.; Nakshatri, H. NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene, 2007, 26(5), 711-724.
166. Wu, Y.; Deng, J.; Rychahou, P. G.; Qiu, S.; Evers, B. M.; Zhou, B. P. Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell, 2009, 15(5), 416-428.
167. Li, S.; Kendall, S. E.; Raices, R.; Finlay, J.; Covarrubias, M.; Liu, Z.; Lowe, G.; Lin, Y. H.; Teh, Y. H.; Leigh, V.; Dhillon, S.; Flanagan, S.; Aboody, K. S.; Glackin, C. A. TWIST1 associates with NF-kappaB subunit RELA via carboxyl-terminal WR domain to promote cell autonomous invasion through IL8 production. BMC Biol, 2012, 10, 73.
168. Li, C. W.; Xia, W.; Huo, L.; Lim, S. O.; Wu, Y.; Hsu, J. L.; Chao, C. H.; Yamaguchi, H.; Yang, N. K.; Ding, Q.; Wang, Y.; Lai, Y. J.; La Baff, A. M.; Wu, T. J.; Lin, B. R.; Yang, M. H.; Hortobagyi, G. N.; Hung, M. C. Epithelial-mesenchymal transition induced by TNF-a requires NFKB-mediated transcriptional upregulation of Twist1. Cancer Res., 2012, 72, (5), 1290-1300.
169. Shibata, A.; Nagaya, T.; Imai, T.; Funahashi, H.; Nakao, A.; Seo, H. Inhibition of NF-kappaB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells. Breast Cancer Res. Treat., 2002, 73(3), 237-243.
170. Li, C; Guo, S.; Shi, T. Role of NF-kappaB activation in matrix metalloproteinase 9, vascular endothelial growth factor and interleukin 8 expression and secretion in human breast cancer cells. Cell Biochem Funct., 2013, 31(3), 263-268.
171. Dai, X. L.; Zhou, S. L.; Qiu, J.; Liu, Y. F.; Hua, H. Correlated expression of Fas, NF-kappaB, and VEGF-C in infiltrating ductal carcinoma of the breast. Eur. J. Gynaecol. Oncol, 2012, 33, 633-639.
172. Yamamoto, M.; Taguchi, Y.; Ito-Kureha, T.; Semba, K.; Yamaguchi, N.; Inoue, J. NF-kappaB non-cell-autonomously regulates cancer stem cell populations in the basal-like breast cancer subtype. Nat. Commun., 2013, 4, 2299.
173. Penault-Llorca, F.; Viale, G. Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective. Ann. Oncol, 2012, 23(Suppl 6), vi19-22.
174. Chougule, M. B.; Patel, A. R.; Jackson, T.; Singh, M. Antitumor activity of Noscapine in combination with Doxorubicin in triple negative breast cancer. PloS on, e 2011, 6(3), e17733.
175. Hartman, Z. C; Poage, G. M.; Den Hollander, P.; Tsimelzon, A.; Hill, J.; Panupinthu, N.; Zhang, Y.; Mazumdar, A.; Hilsenbeck, S. G.; Mills, G. B.; Brown, P. H. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res., 2013, 73(11), 3470-3480.
176. Aggarwal, B. B.; Gehlot, P., Inflammation and cancer: how friendly is the relationship for cancer patients. Curr. Opin. Pharmacol., 2009, 9(4), 351-369.
177. Han, B.; Nakamura, M.; Mori, I.; Nakamura, Y.; Kakudo, K., Urokinase-type plasminogen activator system and breast cancer (Review). Oncol. Rep., 2005, 14(1), 105-112.
178. Van Laere, S.; Limame, R.; Van Marck, E. A.; Vermeulen, P. B.; Dirix, L. Y., Is there a role for mammary stem cells in inflammatory breast carcinoma?: a review of evidence from cell line, animal model, and human tissue sample experiments. Cancer, 2010, 116(11 Suppl), 2794-2805.
179. Merkhofer, E. C.; Cogswell, P.; Baldwin, A. S., Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha. Oncogene, 2010, 29(8), 1238-1248.
180. Makino, K.; Day, C. P.; Wang, S. C.; Li, Y. M.; Hung, M. C., Upregulation of IKKalpha/IKKbeta by integrin-linked kinase is required for HER2/neu-induced NF-kappaB antiapoptotic pathway. Oncogene, 2004, 23(21), 3883-3887.
181. Schramek, D.; Leibbrandt, A.; Sigl, V.; Kenner, L.; Pospisilik, J. A.; Lee, H. J.; Hanada, R.; Joshi, P. A.; Aliprantis, A.; Glimcher, L.; Pasparakis, M.; Khokha, R.; Ormandy, C. J.; Widschwendter, M.; Schett, G.; Penninger, J. M., Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature, 2010, 468(7320), 98-102.
182. Gonzalez-Suarez, E.; Jacob, A. P.; Jones, J.; Miller, R.; Roudier-Meyer, M. P.; Erwert, R.; Pinkas, J.; Branstetter, D.; Dougall, W. C., RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature, 2010, 468(7320), 103-107.
183. Pratt, M. A.; Tibbo, E.; Robertson, S. J.; Jansson, D.; Hurst, K.; Perez-Iratxeta, C.; Lau, R.; Niu, M. Y., The canonical NF-kappaB pathway is required for formation of luminal mammary neoplasias and is activated in the mammary progenitor population. Oncogene, 2009, 28(30), 2710-2722.
184. Zhang, J. Y.; Tao, S.; Kimmel, R.; Khavari, P. A., CDK4 regulation by TNFR1 and JNK is required for NF-kappaB-mediated epidermal growth control. J. Cell. Bio., 2005, 168(4), 561-566.
185. Halazonetis, T. D.; Gorgoulis, V. G.; Bartek, J., An oncogeneinduced DNA damage model for cancer development. Science, 2008, 319(5868), 1352-1355.
186. Brzoska, K.; Szumiel, I., Signalling loops and linear pathways: NF-kappaB activation in response to genotoxic stress. Mutagenesis, 2009, 24(1), 1-8.
187. Hartwig, A.; Blessing, H.; Schwerdtle, T.; Walter, I., Modulation of DNA repair processes by arsenic and selenium compounds. Toxicology, 2003, 193(1-2), 161-169.
188. Volcic, M.; Karl, S.; Baumann, B.; Salles, D.; Daniel, P.; Fulda, S.; Wiesmuller, L., NF-kappaB regulates DNA double-strand break repair in conjunction with BRCA1-CtIP complexes. Nucleic acids Res., 2012, 40(1), 181-195.
189. Hoesel, B.; Schmid, J. A., The complexity of NF-kappaB signaling in inflammation and cancer. Mol. Cancer, 2013, 12, 86.
190. Grivennikov, S. I.; Karin, M., Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev., 2010, 21(1), 11-19.
191. Yang, J.; Liao, X.; Agarwal, M. K.; Barnes, L.; Auron, P. E.; Stark, G. R., Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev., 2007, 21(11), 1396-1408.
192. Lee, H.; Herrmann, A.; Deng, J. H.; Kujawski, M.; Niu, G.; Li, Z.; Forman, S.; Jove, R.; Pardoll, D. M.; Yu, H., Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell, 2009, 15(4), 283-293.
193. Divella, R.; Tommasi, S.; Lacalamita, R.; Daniele, A.; Abbate, I.; Garrisi, V. M.; Savino, E.; Coviello, M.; Rubini, V.; Simone, G.; Paradiso, A.; Quaranta, M., Circulating hTERT DNA in early breast cancer. Anticancer Res., 2009, 29(7), 2845-2849.
194. Wang, Y.; Hu, Z.; Liang, J.; Wang, Z.; Tang, J.; Wang, S.; Wang, X.; Qin, J.; Shen, H., A tandem repeat of human telomerase reverse transcriptase (hTERT) and risk of breast cancer development and metastasis in Chinese women. Carcinogenesis, 2008, 29(6), 1197-1201.
195. Yu, J.; Wang, Y.; Yan, F.; Zhang, P.; Li, H.; Zhao, H.; Yan, C.; Ren, X., Noncanonical NF-kappaB Activation Mediates STAT3-Stimulated IDO Upregulation in Myeloid-Derived Suppressor Cells in Breast Cancer. J Immunol., 2014, 193(5), 2574-2586.
196. Hoeflich, K. P.; Luo, J.; Rubie, E. A.; Tsao, M. S.; Jin, O.; Woodgett, J. R., Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature, 2000, 406(6791), 86-90.
197. Luo, J., Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett., 2009, 273(2), 194-200.
198. Deng, J.; Xia, W.; Miller, S. A.; Wen, Y.; Wang, H. Y.; Hung, M. C., Crossregulation of NF-kappaB by the APC/GSK-3beta/betacatenin pathway. Mol. Carcinog., 2004, 39(3), 139-146.
199. Wang, Y.; Lam, J. B.; Lam, K. S.; Liu, J.; Lam, M. C.; Hoo, R. L.; Wu, D.; Cooper, G. J.; Xu, A., Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res., 2006, 66(23), 11462-11470.
200. Moreau, M.; Mourah, S.; Dosquet, C., beta-Catenin and NF-kappaB cooperate to regulate the uPA/uPAR system in cancer cells. Int. J. Cancer, 2011, 128(6), 1280-1292.
201. Webster, G. A.; Perkins, N. D., Transcriptional cross talk between NF-kappaB and p53. Mol. Cell Biol., 1999, 19(5), 3485-3495.
202. Ryan, K. M.; Ernst, M. K.; Rice, N. R.; Vousden, K. H., Role of NF-kappaB in p53-mediated programmed cell death. Nature, 2000, 404(6780), 892-897.
203. Dalmases, A.; Gonzalez, I.; Menendez, S.; Arpi, O.; Corominas, J. M.; Servitja, S.; Tusquets, I.; Chamizo, C.; Rincon, R.; Espinosa, L.; Bigas, A.; Eroles, P.; Furriol, J.; Lluch, A.; Rovira, A.; Albanell, J.; Rojo, F., Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-small ka, CyrillicB target genes in human breast cancer. Oncotarget, 2014, 5(1), 196-210.
204. Schneider, G.; Kramer, O. H., NFkappaB/p53 crosstalk-a promising new therapeutic target. Biochim. Biophys. Acta, 2011, 1815(1), 90-103.
205. Schneider, G.; Henrich, A.; Greiner, G.; Wolf, V.; Lovas, A.; Wieczorek, M.; Wagner, T.; Reichardt, S.; Von Werder, A.; Schmid, R. M.; Weih, F.; Heinzel, T.; Saur, D.; Kramer, O. H., Cross talk between stimulated NF-kappaB and the tumor suppressor p53. Oncogene, 2010, 29(19), 2795-2806.
206. Zhou, M.; Gu, L.; Findley, H. W.; Jiang, R.; Woods, W. G., PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res., 2003, 63(19), 6357-6362.
207. Thomasova, D.; Mulay, S. R.; Bruns, H.; Anders, H. J., p53-independent roles of MDM2 in NF-kappaB signaling: implications for cancer therapy, wound healing, and autoimmune diseases. Neoplasia, 2012, 14(12), 1097-1101.
208. Busuttil, V.; Droin, N.; McCormick, L.; Bernassola, F.; Candi, E.; Melino, G.; Green, D. R., NF-kappaB inhibits T-cell activationinduced, p73-dependent cell death by induction of MDM2. Proc. Natl. Acad. Sci. USA., 2010, 107(42), 18061-18066.
209. Pianetti, S.; Arsura, M.; Romieu-Mourez, R.; Coffey, R. J.; Sonenshein, G. E., Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene, 2001, 20(11), 1287-1299.
210. Shapira, I.; Lee, A.; Vora, R.; Budman, D. R., P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency. Crit. Rev. Oncol. Hematol., 2013, 88(2), 284-292.
211. Qian, B.; Nag, S. A.; Su, Y.; Voruganti, S.; Qin, J. J.; Zhang, R.; Cho, W. C., miRNAs in cancer prevention and treatment and as molecular targets for natural product anticancer agents. Curr. Cancer Drug Targets, 2013, 13(5), 519-541.
212. Bazzoni, F.; Rossato, M.; Fabbri, M.; Gaudiosi, D.; Mirolo, M.; Mori, L.; Tamassia, N.; Mantovani, A.; Cassatella, M. A.; Locati, M., Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals. Proc. Natl. Acad. Sci. USA., 2009, 106(13), 5282-5287.
213. Ma, X.; Becker Buscaglia, L. E.; Barker, J. R.; Li, Y., MicroRNAs in NF-kappaB signaling. J. Mol. Cell Biol., 2011, 3(3), 159-166.
214. Bhaumik, D.; Scott, G. K.; Schokrpur, S.; Patil, C. K.; Campisi, J.; Benz, C. C., Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene, 2008, 27(42), 5643-5647.
215. Iorio, M. V.; Ferracin, M.; Liu, C. G.; Veronese, A.; Spizzo, R.; Sabbioni, S.; Magri, E.; Pedriali, M.; Fabbri, M.; Campiglio, M.; Menard, S.; Palazzo, J. P.; Rosenberg, A.; Musiani, P.; Volinia, S.; Nenci, I.; Calin, G. A.; Querzoli, P.; Negrini, M.; Croce, C. M., MicroRNA gene expression deregulation in human breast cancer. Cancer Res., 2005, 65(16), 7065-7070.
216. Niu, J.; Shi, Y.; Tan, G.; Yang, C. H.; Fan, M.; Pfeffer, L. M.; Wu, Z. H., DNA damage induces NF-kappaB-dependent microRNA-21 up-regulation and promotes breast cancer cell invasion. J. Biol. Chem., 2012, 287(26), 21783-21795.
217. Howe, E. N.; Cochrane, D. R.; Cittelly, D. M.; Richer, J. K., miR-200c targets a NF-kappaB up-regulated TrkB/NTF3 autocrine signaling loop to enhance anoikis sensitivity in triple negative breast cancer. PloS one, 2012, 7(11), e49987.
218. Keklikoglou, I.; Koerner, C.; Schmidt, C.; Zhang, J. D.; Heckmann, D.; Shavinskaya, A.; Allgayer, H.; Guckel, B.; Fehm, T.; Schneeweiss, A.; Sahin, O.; Wiemann, S.; Tschulena, U., MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kappaB and TGF-beta signaling pathways. Oncogene, 2012, 31(37), 4150-4163.
219. Sorlie, T.; Perou, C. M.; Tibshirani, R.; Aas, T.; Geisler, S.; Johnsen, H.; Hastie, T.; Eisen, M. B.; Van De Rijn, M.; Jeffrey, S. S.; Thorsen, T.; Quist, H.; Matese, J. C.; Brown, P. O.; Botstein, D.; Lonning, P. E.; Borresen-Dale, A. L., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA., 2001, 98(19), 10869-10874.
220. The Cancer Genome Atlas Network, Comprehensive molecular portraits of human breast tumors. Nature, 2012, 490, 61-70.
221. Perou, C. M.; Sorlie, T.; Eisen, M. B.; Van De Rijn, M.; Jeffrey, S. S.; Rees, C. A.; Pollack, J. R.; Ross, D. T.; Johnsen, H.; Akslen, L. A.; Fluge, O.; Pergamenschikov, A.; Williams, C.; Zhu, S. X.; Lonning, P. E.; Borresen-Dale, A. L.; Brown, P. O.; Botstein, D., Molecular portraits of human breast tumours. Nature, 2000, 406(6797), 747-752.
222. Bertucci, F.; Birnbaum, D., Reasons for breast cancer heterogeneity. J. Biol., 2008, 7(2), 6.
223. Hsiao, Y. H.; Chou, M. C.; Fowler, C.; Mason, J. T.; Man, Y. G., Breast cancer heterogeneity: mechanisms, proofs, and implications. J. Cancer, 2010, 1, 6-13.
224. Fan, C.; Oh, D. S.; Wessels, L.; Weigelt, B.; Nuyten, D. S.; Nobel, A. B.; Van't Veer, L. J.; Perou, C. M., Concordance among geneexpression-based predictors for breast cancer. N. Eng. J. Med., 2006, 355(6), 560-569.
225. Sikora, M. J.; Cooper, K. L.; Bahreini, A.; Luthra, S.; Wang, G.; Chandran, U. R.; Davidson, N. E.; Dabbs, D. J.; Welm, A. L.; Oesterreich, S., Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response. Cancer Res., 2014. 74(5), 1463-1474.
226. Creighton, C. J.; Hilger, A. M.; Murthy, S.; Rae, J. M.; Chinnaiyan, A. M.; El-Ashry, D., Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res., 2006, 66(7), 3903-3911.
227. Sas, L.; Lardon, F.; Vermeulen, P. B.; Hauspy, J.; Van Dam, P.; Pauwels, P.; Dirix, L. Y.; Van Laere, S. J., The interaction between ER and NFkappaB in resistance to endocrine therapy. Breast Cancer Res., 2012, 14(4), 212.
228. Galien, R.; Garcia, T., Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-kappaB site. Nucleic acids Res., 1997, 25(12), 2424-2429.
229. Wang, X.; Belguise, K.; Kersual, N.; Kirsch, K. H.; Mineva, N. D.; Galtier, F.; Chalbos, D.; Sonenshein, G. E., Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat. Cell Biol., 2007, 9(4), 470-478.
230. Belguise, K.; Sonenshein, G. E., PKCtheta promotes c-Rel-driven mammary tumorigenesis in mice and humans by repressing estrogen receptor alpha synthesis. J. Clin. Invest., 2007, 117(12), 4009-4021.
231. Wang, X.; Belguise, K.; O'Neill, C. F.; Sanchez-Morgan, N.; Romagnoli, M.; Eddy, S. F.; Mineva, N. D.; Yu, Z.; Min, C.; Trinkaus-Randall, V.; Chalbos, D.; Sonenshein, G. E., RelB NF-kappaB represses estrogen receptor alpha expression via induction of the zinc finger protein Blimp1. Mol. Cell. Biol., 2009, 29(14), 3832-3844.
232. Reijm, E. A.; Jansen, M. P.; Ruigrok-Ritstier, K.; Van Staveren, I. L.; Look, M. P.; Van Gelder, M. E.; Sieuwerts, A. M.; Sleijfer, S.; Foekens, J. A.; Berns, E. M., Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer. Breast Cancer Res. Treat., 2011, 125(2), 387-394.
233. Paimela, T.; Ryhanen, T.; Mannermaa, E.; Ojala, J.; Kalesnykas, G.; Salminen, A.; Kaarniranta, K., The effect of 17beta-estradiol on IL-6 secretion and NF-kappaB DNA-binding activity in human retinal pigment epithelial cells. Immunol. Lett., 2007, 110(2), 139-144.
234. Dai, R.; Phillips, R. A.; Ahmed, S. A., Despite inhibition of nuclear localization of NF-kappa B p65, c-Rel, and RelB, 17-beta estradiol up-regulates NF-kappa B signaling in mouse splenocytes: the potential role of Bcl-3. J. Immunol., 2007, 179(3), 1776-1783.
235. Ghisletti, S.; Meda, C.; Maggi, A.; Vegeto, E., 17beta-estradiol inhibits inflammatory gene expression by controlling NF-kappaB intracellular localization. Mol. Cell. Biol., 2005, 25(8), 2957-2968.
236. Nettles, K. W.; Gil, G.; Nowak, J.; Metivier, R.; Sharma, V. B.; Greene, G. L., CBP Is a dosage-dependent regulator of nuclear factor-kappaB suppression by the estrogen receptor. Mol Endocrinol., 2008, 22(2), 263-272.
237. Cvoro, A.; Tzagarakis-Foster, C.; Tatomer, D.; Paruthiyil, S.; Fox, M. S.; Leitman, D. C., Distinct roles of unliganded and liganded estrogen receptors in transcriptional repression. Mol. Cell, 2006, 21(4), 555-564.
238. Frasor, J.; Weaver, A.; Pradhan, M.; Dai, Y.; Miller, L. D.; Lin, C. Y.; Stanculescu, A., Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer. Cancer Res., 2009, 69(23), 8918-8925.
239. De Graffenried, L. A.; Chandrasekar, B.; Friedrichs, W. E.; Donzis, E.; Silva, J.; Hidalgo, M.; Freeman, J. W.; Weiss, G. R., NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann. Oncol., 2004, 15(6), 885-890.
240. Gerondakis, S.; Grumont, R.; Gugasyan, R.; Wong, L.; Isomura, I.; Ho, W.; Banerjee, A., Unravelling the complexities of the NF-kappaB signalling pathway using mouse knockout and transgenic models. Oncogene, 2006, 25(51), 6781-6799.
241. Gerondakis, S.; Grossmann, M.; Nakamura, Y.; Pohl, T.; Grumont, R., Genetic approaches in mice to understand Rel/NF-kappaB and IkappaB function: transgenics and knockouts. Oncogene, 1999, 18(49), 6888-6895.
242. Beinke, S.; Ley, S. C., Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem. J., 2004, 382(Pt 2), 393-409.
243. Courtois, G.; Gilmore, T. D., Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene, 2006, 25(51), 6831-6843.
244. Beg, A. A.; Sha, W. C.; Bronson, R. T.; Ghosh, S.; Baltimore, D., Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature, 1995, 376(6536), 167-170.
245. Cao, Y.; Bonizzi, G.; Seagroves, T. N.; Greten, F. R.; Johnson, R.; Schmidt, E. V.; Karin, M., IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell, 2001, 107(6), 763-775.
246. Li, F.; Sethi, G., Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim. Biophys. Acta, 2010, 1805(2), 167-180.
247. Musgrove, E. A.; Sutherland, R. L., Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer, 2009, 9(9), 631-643.
248. Pradhan, M.; Bembinster, L. A.; Baumgarten, S. C.; Frasor, J., Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NF{kappa}B cooperativity at adjacent response elements. J. Biol. Chem., 2010, 285(41), 31100-31106.
249. Wang, X.; Wu, X.; Wang, C.; Zhang, W.; Ouyang, Y.; Yu, Y.; He, Z., Transcriptional suppression of breast cancer resistance protein (BCRP) by wild-type p53 through the NF-kappaB pathway in MCF-7 cells. FEBS letters, 2010, 584(15), 3392-3397.
250. Wang, Y.; Wang, X.; Zhao, H.; Liang, B.; Du, Q., Clusterin confers resistance to TNF-alpha-induced apoptosis in breast cancer cells through NF-kappaB activation and Bcl-2 overexpression. J. Chemother., 2012, 24(6), 348-357.
251. Wang, Q. P.; Wang, Y.; Wang, X. D.; Mo, X. M.; Gu, J.; Lu, Z. Y.; Pan, Z. L.; Zhu, Y. X., Survivin up-regulates the expression of breast cancer resistance protein (BCRP) through attenuating the suppression of p53 on NF-kappaB expression in MCF-7/5-FU cells. Int. J. Biochem. Cell Biol., 2013, 45(9), 2036-2044.
252. Esparza-Lopez, J.; Medina-Franco, H.; Escobar-Arriaga, E.; Leon-Rodriguez, E.; Zentella-Dehesa, A.; Ibarra-Sanchez, M. J., Doxorubicin induces atypical NF-kappaB activation through c-Abl kinase activity in breast cancer cells. J. Cancer Res. Clin. Oncol., 2013, 139(10), 1625-1635.
253. Ho, W. C.; Dickson, K. M.; Barker, P. A., Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-kappaB-dependent transcription in cancer cells. Cancer Res., 2005, 65(10), 4273-4281.
254. Korkaya, H.; Kim, G. I.; Davis, A.; Malik, F.; Henry, N. L.; Ithimakin, S.; Quraishi, A. A.; Tawakkol, N.; D'Angelo, R.; Paulson, A. K.; Chung, S.; Luther, T.; Paholak, H. J.; Liu, S.; Hassan, K. A.; Zen, Q.; Clouthier, S. G.; Wicha, M. S., Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol. Cell, 2012, 47(4), 570-584.
255. Xia, W.; Bacus, S.; Husain, I.; Liu, L.; Zhao, S.; Liu, Z.; Moseley, M. A., 3rd; Thompson, J. W.; Chen, F. L.; Koch, K. M.; Spector, N. L., Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA. Mol. Cancer Ther., 2010, 9(2), 292-299.
256. Park, K. J.; Krishnan, V.; O'Malley, B. W.; Yamamoto, Y.; Gaynor, R. B., Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation. Mol. Cell, 2005, 18(1), 71-82.
257. Nam, J. M.; Ahmed, K. M.; Costes, S.; Zhang, H.; Onodera, Y.; Olshen, A. B.; Hatanaka, K. C.; Kinoshita, R.; Ishikawa, M.; Sabe, H.; Shirato, H.; Park, C. C., Beta1-integrin via NF-kappaB signaling is essential for acquisition of invasiveness in a model of radiation treated in situ breast cancer. Breast Cancer Res., 2013, 15(4), R60.
258. Huang, Y.; Fan, W., IkappaB kinase activation is involved in regulation of paclitaxel-induced apoptosis in human tumor cell lines. Mol. Pharmacol., 2002, 61(1), 105-113.
259. Ahmed, K. M.; Zhang, H.; Park, C. C., NF-kappaB regulates radioresistance mediated by beta1-integrin in three-dimensional culture of breast cancer cells. Cancer Res., 2013, 73(12), 3737-3748.
260. Brach, M. A.; Hass, R.; Sherman, M. L.; Gunji, H.; Weichselbaum, R.; Kufe, D., Ionizing radiation induces expression and binding activity of the nuclear factor kappa B. J. Clin. Invest., 1991, 88(2), 691-695.
261. Li, N.; Karin, M., Ionizing radiation and short wavelength UV activate NF-kappaB through two distinct mechanisms., Proc. Natl. Acad. Sci. USA., 1998, 95(22), 13012-13017.
262. Ahmed, K. M.; Dong, S.; Fan, M.; Li, J. J., Nuclear factor-kappaB p65 inhibits mitogen-activated protein kinase signaling pathway in radioresistant breast cancer cells. Mol. Cancer Res., 2006, 4(12), 945-955.
263. Cao, N.; Li, S.; Wang, Z.; Ahmed, K. M.; Degnan, M. E.; Fan, M.; Dynlacht, J. R.; Li, J. J., NF-kappaB-mediated HER2 overexpression in radiation-adaptive resistance. Radiation Res., 2009, 171(1), 9-21.
264. Aggarwal, B. B.; Van Kuiken, M. E.; Iyer, L. H.; Harikumar, K. B.; Sung, B., Molecular targets of nutraceuticals derived from dietary spices: potential role in suppression of inflammation and tumorigenesis. Exp. Biol. Med. (Maywood), 2009, 234(8), 825-849.
265. Aggarwal, B. B.; Shishodia, S.; Takada, Y.; Banerjee, S.; Newman, R. A.; Bueso-Ramos, C. E.; Price, J. E., Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin. Cancer Res., 2005, 11(20), 7490-7498.
266. Howe, L. R.; Subbaramaiah, K.; Patel, J.; Masferrer, J. L.; Deora, A.; Hudis, C.; Thaler, H. T.; Muller, W. J.; Du, B.; Brown, A. M.; Dannenberg, A. J., Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res., 2002, 62(19), 5405-5407.
267. Nag, S. A.; Qin, J. J.; Wang, W.; Wang, M. H.; Wang, H.; Zhang, R., Ginsenosides as Anticancer Agents: In vitro and in vivo Activities, Structure-Activity Relationships, and Molecular Mechanisms of Action. Front. Pharmacol., 2012, 3, 25.
268. Li, L.; Wang, Y.; Qi, B.; Yuan, D.; Dong, S.; Guo, D.; Zhang, C.; Yu, M., Suppression of PMA-induced tumor cell invasion and migration by ginsenoside Rg1 via the inhibition of NF-kappaB-dependent MMP-9 expression. Oncol. Rep., 2014, 32(5), 1779-1786.
269. Kim, B. M.; Kim, D. H.; Park, J. H.; Surh, Y. J.; Na, H. K., Ginsenoside Rg3 Inhibits Constitutive Activation of NF-kB Signaling in Human Breast Cancer (MDA-MB-231) Cells: ERK and Akt as Potential Upstream Targets. J. Cancer. Prev., 2014, 19, 23-30.
270. Peralta, E. A.; Murphy, L. L.; Minnis, J.; Louis, S.; Dunnington, G. L., American Ginseng inhibits induced COX-2 and NFKB activation in breast cancer cells. J. Surg. Res., 2009, 157(2), 261-267.
271. Rebbeck, T. R.; Troxel, A. B.; Norman, S.; Bunin, G. R.; De Michele, A.; Baumgarten, M.; Berlin, M.; Schinnar, R.; Strom, B. L., A retrospective case-control study of the use of hormone-related supplements and association with breast cancer. Int. J. Cancer, 2007, 120(7), 1523-1528.
272. Cui, Y.; Shu, X. O.; Gao, Y. T.; Cai, H.; Tao, M. H.; Zheng, W., Association of ginseng use with survival and quality of life among breast cancer patients. Am. J. Epedemiol, 2006, 163(7), 645-653.
273. Lee, S. Y.; Seol, J. Y.; Park, K. H.; Park, G. M.; Hwang, Y. I.; Kim, C. H.; Jang, S. H.; Kwon, S. Y.; Yoo, C. G.; Kim, Y. W.; Han, S. K.; Shim, Y. S.; Lee, C. T. The Effect of IκBα-SR Gene Transfer on the Sensitivity of Human Lung Cancer Cell Lines to Cisplatin and Paclitaxel. Tuberc. Respir. Dis. (Seoul), 2001, 51(2), 122-134.
274. Higgins, K. A.; Perez, J. R.; Coleman, T. A.; Dorshkind, K.; McComas, W. A.; Sarmiento, U. M.; Rosen, C. A.; Narayanan, R., Antisense inhibition of the p65 subunit of NF-kappa B blocks tumorigenicity and causes tumor regression. Proc. Natl. Acad. Sci. USA., 1993, 90(21), 9901-9905.
275. Xu, Y.; Fang, F.; St Clair, D. K.; Sompol, P.; Josson, S.; St Clair, W. H., SN52, a novel nuclear factor-kappaB inhibitor, blocks nuclear import of RelB: p52 dimer and sensitizes prostate cancer cells to ionizing radiation. Mol. Cancer Ther., 2008, 7(8), 2367-2376.
276. Mabuchi, S.; Ohmichi, M.; Nishio, Y.; Hayasaka, T.; Kimura, A.; Ohta, T.; Saito, M.; Kawagoe, J.; Takahashi, K.; Yada-Hashimoto, N.; Sakata, M.; Motoyama, T.; Kurachi, H.; Tasaka, K.; Murata, Y., Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J. Biol. Chem., 2004, 279(22), 23477-23485.
277. Vinod, B. S.; Antony, J.; Nair, H. H.; Puliyappadamba, V. T.; Saikia, M.; Narayanan, S. S.; Bevin, A.; Anto, R. J., Mechanistic evaluation of the signaling events regulating curcumin-mediated chemosensitization of breast cancer cells to 5-fluorouracil. Cell Death Dis., 2013, 4, e505.
278. Orange, J. S.; May, M. J., Cell penetrating peptide inhibitors of nuclear factor-kappa B. Cell Mol. Life Sci., 2008, 65(22), 3564-3591.
279. Fabre, C; Mimura, N.; Bobb, K.; Kong, S. Y.; Gorgun, G.; Cirstea, D.; Hu, Y.; Minami, J.; Ohguchi, H.; Zhang, J.; Meshulam, J.; Carrasco, R. D.; Tai, Y. T.; Richardson, P. G.; Hideshima, T.; Anderson, K. C, Dual inhibition of canonical and noncanonical NF-kappaB pathways demonstrates significant antitumor activities in multiple myeloma. Clin. Cancer Res., 2012, 18(17), 4669-4681.
280. Hunter, J. E.; Willmore, E.; Irving, J. A.; Sliskovic, D.; Monie, D.; Bobb, K.; Zhang, J.; Durkacz, B. W. The radiosensitizing and cytotoxic effects of PBS-1086, a Rel inhibitor of NF-KB, in breast cancer cells. Cancer Res., 2010, 70(8 Supplement), 3561.
281. Patel, N. M.; Nozaki, S.; Shortle, N. H.; Bhat-Nakshatri, P.; Newton, T. R.; Rice, S.; Gelfanov, V.; Boswell, S. H.; Goulet, R. J., Jr.; Sledge, G. W., Jr.; Nakshatri, H., Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene, 2000, 19(36), 4159-4169.
282. Zhou, J.; Zhang, H.; Gu, P.; Bai, J.; Margolick, J. B.; Zhang, Y., NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res. Treat., 2008, 111(3), 419-427.
283. Matsumoto, N.; Ariga, A.; Toe, S.; Nakamura, H.; Agata, N.; Hirano, S.; Inoue, J.; Umezawa, K., Synthesis of NF-kappaB activation inhibitors derived from epoxyquinomicin C. Bioorg. Med. Chem. Lett., 2000, 10(9), 865-869.
284. Matsumoto, G.; Namekawa, J.; Muta, M.; Nakamura, T.; Bando, H.; Tohyama, K.; Toi, M.; Umezawa, K., Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin. Cancer Res., 2005, 11(3), 1287-1293.
285. Takada, Y.; Gillenwater, A.; Ichikawa, H.; Aggarwal, B. B., Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J. Biol. Chem., 2006, 281(9), 5612-5622.
286. Domingo-Domenech, J.; Pippa, R.; Tapia, M.; Gascon, P.; Bachs, O.; Bosch, M., Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells. Breast Cancer Res. Treat., 2008, 112(1), 53-62.
287. Grant, S., Advances in Cancer Research Volume 116, Histone Deacetylase Inhibitors as Cancer Therapeutics. Academic Press, 2012.
288. Disch, J. S.; Evindar, G.; Chiu, C. H.; Blum, C. A.; Dai, H.; Jin, L.; Schuman, E.; Lind, K. E.; Belyanskaya, S. L.; Deng, J.; Coppo, F.; Aquilani, L.; Graybill, T. L.; Cuozzo, J. W.; Lavu, S.; Mao, C; Vlasuk, G. P.; Perni, R. B., Discovery of thieno[3, 2-d]pyrimidine-6-carboxamides as potent inhibitors of SIRT1, SIRT2, and SIRT3. J. Med. Chem., 2013, 56(9), 3666-3679.
289. Fernandes, C. A.; Fievez, L.; Neyrinck, A. M.; Delzenne, N. M.; Bureau, F.; Vanbever, R., Sirtuin inhibition attenuates the production of inflammatory cytokines in lipopolysaccharide-stimulated macrophages. Biochem. Biophys. Res. Comm., 2012, 420(4), 857-861.
290. Yang, C. H.; Gonzalez-Angulo, A. M.; Reuben, J. M.; Booser, D. J.; Pusztai, L.; Krishnamurthy, S.; Esseltine, D.; Stec, J.; Broglio, K. R.; Islam, R.; Hortobagyi, G. N; Cristofanilli, M., Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann. Oncol, 2006, 17(5), 813-817.
291. Chen, D.; Frezza, M.; Schmitt, S.; Kanwar, J.; Dou, Q. P., Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr. Cancer Drug Targets, 2011, 11(3), 239-253.
292. Kuhn, D. J.; Chen, Q.; Voorhees, P. M.; Strader, J. S.; Shenk, K. D.; Sun, C. M.; Demo, S. D.; Bennett, M. K.; Van Leeuwen, F. W.; Chanan-Khan, A. A.; Orlowski, R. Z., Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood, 2007, 110(9), 3281-3290.
293. Shank, B. R.; Brown, V. T.; Schwartz, R. N., Multiple myeloma maintenance therapy: A review of the pharmacologic treatment. J. Oncol. Pharm. Pract., 2014.
294. Molineaux, S. M., Molecular pathways: targeting proteasomal protein degradation in cancer. Clin. Cancer Res., 2012, 18(1), 15-20.
295. Fuchs, O., Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma. Cardiovasc. Hematol Disord. Drug Targets, 2013, 13(1), 16-34.
296. Soucy, T. A.; Smith, P. G; Milhollen, M. A.; Berger, A. J.; Gavin, J. M.; Adhikari, S.; Brownell, J. E.; Burke, K. E.; Cardin, D. P.; Critchley, S.; Cullis, C. A.; Doucette, A.; Garnsey, J. J.; Gaulin, J. L.; Gershman, R. E.; Lublinsky, A. R.; McDonald, A.; Mizutani, H.; Narayanan, U.; Olhava, E. J.; Peluso, S.; Rezaei, M.; Sintchak, M. D.; Talreja, T.; Thomas, M. P.; Traore, T.; Vyskocil, S.; Weatherhead, G. S.; Yu, J.; Zhang, J.; Dick, L. R.; Claiborne, C. F.; Rolfe, M.; Bolen, J. B.; Langston, S. P., An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature, 2009, 458(7239), 732-736.
297. Gomez-Cabrero, A.; Wrasidlo, W.; Reisfeld, R. A., IMD-0354 targets breast cancer stem cells: a novel approach for an adjuvant to chemotherapy to prevent multidrug resistance in a murine model. PloS one, 2013, 8(8), e73607.
298. Viola, K.; Kopf, S.; Huttary, N.; Vonach, C; Kretschy, N.; Teichmann, M.; Giessrigl, B.; Raab, I.; Stary, S.; Krieger, S.; Keller, T.; Bauer, S.; Hantusch, B.; Szekeres, T.; De Martin, R.; Jager, W.; Mikulits, W.; Dolznig, H.; Krupitza, G.; Grusch, M., Bay1 1-7082 inhibits the disintegration of the lymphendothelial barrier triggered by MCF-7 breast cancer spheroids; the role of ICAM-1 and adhesion. Br. J. Cancer, 2013, 108(3), 564-569.
299. Peinado, C; Kang, X.; Hardamon, C; Arora, S.; Mah, S.; Zhang, H.; Ngolab, J.; Bui, J. D., The nuclear factor-kappaB pathway down-regulates expression of the NKG2D ligand H60a in vitro: implications for use of nuclear factor-kappaB inhibitors in cancer therapy. Immunology, 2013, 139(2), 265-274.
300. Hideshima, T.; Neri, P.; Tassone, P.; Yasui, H.; Ishitsuka, K.; Raje, N; Chauhan, D.; Podar, K.; Mitsiades, C; Dang, L.; Munshi, N; Richardson, P.; Schenkein, D.; Anderson, K. C, MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clinical Cancer Res., 2006, 12(19), 5887-5894.
301. Singh, S.; Shi, Q.; Bailey, S. T.; Palczewski, M. J.; Pardee, A. B.; Iglehart, J. D.; Biswas, D. K., Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer. Mol. Cancer Ther., 2007, 6(7), 1973-1982.
302. Casas, A.; Llombart, A.; Martin, M., Denosumab for the treatment of bone metastases in advanced breast cancer. Breast, 2013, 22(5), 585-592.
303. Liu, D.; Chen, Z., The effect of curcumin on breast cancer cells. J. Breast Cancer, 2013, 16(2), 133-137.
304. Pozo-Guisado, E.; Merino, J. M.; Mulero-Navarro, S.; Lorenzo-Benayas, M. J.; Centeno, F.; Alvarez-Barrientos, A.; Fernandez-Salguero, P. M., Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kappaB. Int. J. Cancer, 2005, 115(1), 74-84.
305. Sethi, G.; Ahn, K. S.; Aggarwal, B. B., Targeting nuclear factorkappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol. Cancer Res., 2008, 6(6), 1059-1070.
306. Loganathan, R.; Selvaduray, K. R.; Nesaretnam, K.; Radhakrishnan, A. K., Tocotrienols promote apoptosis in human breast cancer cells by inducing poly (ADP-ribose) polymerase cleavage and inhibiting nuclear factor kappa-B activity. Cell Prolif., 2013, 46(2), 203-213.
307. Chattopadhyay, M.; Kodela, R.; Nath, N.; Barsegian, A.; Boring, D.; Kashfi, K., Hydrogen sulfide-releasing aspirin suppresses NF-kappaB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo. Biochem. Pharmacol. 2012, 83(6), 723-732.
308. Du Bois, R. N., Aspirin and breast cancer prevention - The estrogen connection. J. Am. Med. Assoc., 2004, 291(20), 2488-2489.
309. Lazzeroni, M.; Petrera, M.; Marra, D.; De Censi, A., Aspirin and Breast Cancer Prevention. Curr. Breast Cancer Rep., 2013, 5(3), 202-207.
310. Wang, H.; Wang, Y.; Rayburn, E. R.; Hill, D. L.; Rinehart, J. J.; Zhang, R., Dexamethasone as a chemosensitizer for breast cancer chemotherapy: potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics. Int. J. Oncol., 2007, 30(4), 947-953.
311. Campbell, M. J.; Esserman, L. J.; Zhou, Y.; Shoemaker, M.; Lobo, M.; Borman, E.; Baehner, F.; Kumar, A. S.; Adduci, K.; Marx, C.; Petricoin, E. F.; Liotta, L. A.; Winters, M.; Benz, S.; Benz, C. C., Breast cancer growth prevention by statins. Cancer Res., 2006, 66(17), 8707-8714.
312. Denoyelle, C.; Vasse, M.; Korner, M.; Mishal, Z.; Ganne, F.; Vannier, J. P.; Soria, J.; Soria, C., Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis, 2001, 22(8), 1139-1148.
313. Carey, L. A.; Rugo, H. S.; Marcom, P. K.; Mayer, E. L.; Esteva, F. J.; Ma, C. X.; Liu, M. C.; Storniolo, A. M.; Rimawi, M. F.; Forero-Torres, A.; Wolff, A. C.; Hobday, T. J.; Ivanova, A.; Chiu, W. K.; Ferraro, M.; Burrows, E.; Bernard, P. S.; Hoadley, K. A.; Perou, C. M.; Winer, E. P., TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triplenegative breast cancer. J. Clin. Oncol., 2012, 30(21), 2615-2623.
314. Krempski, J.; Karyampudi, L.; Behrens, M. D.; Erskine, C. L.; Hartmann, L.; Dong, H.; Goode, E. L.; Kalli, K. R.; Knutson, K. L., Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J. Immunol., 2011, 186(12), 6905-6913.
315. Ascierto, Paolo A.; Munn, D. H.; Palucka, A. K.; Sondel, P. M., Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer. J. Immunother. Cancer, 2014, 2, 15.
316. Qin, J. J.; Jin, H. Z.; Huang, Y.; Zhang, S. D.; Shan, L.; Voruganti, S.; Nag, S.; Wang, W.; Zhang, W. D.; Zhang, R., Selective cytotoxicity, inhibition of cell cycle progression, and induction of apoptosis in human breast cancer cells by sesquiterpenoids from Inula lineariifolia Turcz. Eur. J. Med. Chem., 2013, 68, 473-481.
317. Li, X.; Yang, X.; Liu, Y.; Gong, N.; Yao, W.; Chen, P.; Qin, J.; Jin, H.; Li, J.; Chu, R.; Shan, L.; Zhang, R.; Zhang, W.; Wang, H., Japonicone A suppresses growth of Burkitt lymphoma cells through its effect on NF-kappaB. Clin. Cancer Res., 2013, 19(11), 2917-2928.
318. Galanis, A.; Pappa, A.; Giannakakis, A.; Lanitis, E.; Dangaj, D.; Sandaltzopoulos, R., Reactive oxygen species and HIF-1 signalling in cancer. Cancer Lett., 2008, 266(1), 12-20.
319. Siomek, A., NF-kappaB signaling pathway and free radical impact. Acta Biochim. Pol., 2012, 59(3), 323-331.
320. Epinat, J. C.; Gilmore, T. D., Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway. Oncogene, 1999, 18(49), 6896-6909.
321. Adhikary, A.; Mohanty, S.; Lahiry, L.; Hossain, D. M.; Chakraborty, S.; Das, T., Theaflavins retard human breast cancer cell migration by inhibiting NF-kappaB via p53-ROS cross-talk. FEBS Lett., 2010, 584(1), 7-14.
322. Eytan, E.; Ganoth, D.; Armon, T.; Hershko, A., ATP-dependent incorporation of 20S protease into the 26S complex that degrades proteins conjugated to ubiquitin. Proc. Natl. Acad. Sci. USA., 1989, 86(20), 7751-7755.
323. Tanaka, K.; Mizushima, T.; Saeki, Y., The proteasome: molecular machinery and pathophysiological roles. Biol. Chem., 2012, 393(4), 217-234.
324. Kisselev, A. F.; Van Der Linden, W. A.; Overkleeft, H. S., Proteasome inhibitors: an expanding army attacking a unique target. Chem. Biol., 2012, 19(1), 99-115.
325. Russo, S. M.; Tepper, J. E.; Baldwin, A. S., Jr.; Liu, R.; Adams, J.; Elliott, P.; Cusack, J. C., Jr., Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int. J. Rad. Oncol. Biol. Phys., 2001, 50(1), 183-193.
326. Cardoso, F.; Durbecq, V.; Laes, J. F.; Badran, B.; Lagneaux, L.; Bex, F.; Desmedt, C.; Willard-Gallo, K.; Ross, J. S.; Burny, A.; Piccart, M.; Sotiriou, C., Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner. Mol. Cancer Ther., 2006, 5(12), 3042-3051.
327. Brandao, R. D.; Veeck, J.; Van De Vijver, K. K.; Lindsey, P.; De Vries, B.; Van Elssen, C. H.; Blok, M. J.; Keymeulen, K.; Ayoubi, T.; Smeets, H. J.; Tjan-Heijnen, V. C.; Hupperets, P. S., A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer. Breast Cancer Res., 2013, 15(2), R29.
328. Van Wijngaarden, J.; Van Beek, E.; Van Rossum, G.; Van Der Bent, C.; Hoekman, K.; Van Der Pluijm, G.; Van Der Pol, M. A.; Broxterman, H. J.; Van Hinsbergh, V. W.; Lowik, C. W., Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation. Eur. J. Cancer, 2007, 43(2), 433-442.
329. Wang, L.; Kang, F.; Li, J.; Zhang, J.; Shan, B., Overexpression of p65 attenuates celecoxib-induced cell death in MDA-MB-231 human breast cancer cell line. Cancer Cell Int., 2013, 13(1), 14.
330. Yamamoto, Y.; Yin, M. J.; Lin, K. M.; Gaynor, R. B., Sulindac inhibits activation of the NF-kappaB pathway. J. Biol. Chem., 1999, 274(38), 27307-27314.
331. Scheinman, R. I.; Gualberto, A.; Jewell, C. M.; Cidlowski, J. A.; Baldwin, A. S., Jr., Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Mol. Cell Biol., 1995, 15(2), 943-953.
332. McKay, L. I.; Cidlowski, J. A., CBP (CREB binding protein) integrates NF-kappaB (nuclear factor-kappaB) and glucocorticoid receptor physical interactions and antagonism. Mol. Endocrinol., 2000, 14(8), 1222-1234.
333. Gamble, C.; McIntosh, K.; Scott, R.; Ho, K. H.; Plevin, R.; Paul, A., Inhibitory kappa B Kinases as targets for pharmacological regulation. Br. J. Pharmacol., 2012, 165(4), 802-819.
334. Biswas, D. K.; Shi, Q.; Baily, S.; Strickland, I.; Ghosh, S.; Pardee, A. B.; Iglehart, J. D., NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc. Natl. Acad. Sci. USA., 2004, 101(27), 10137-10142.
335. Meffert, M. K.; Chang, J. M.; Wiltgen, B. J.; Fanselow, M. S.; Baltimore, D., NF-kappa B functions in synaptic signaling and behavior. Nature Neuroscience 2003, 6(10), 1072-1078.
336. Luedde, T.; Beraza, N.; Kotsikoris, V.; Van Loo, G.; Nenci, A.; De Vos, R.; Roskams, T.; Trautwein, C.; Pasparakis, M., Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell, 2007, 11(2), 119-132.
337. Maeda, S.; Kamata, H.; Luo, J. L.; Leffert, H.; Karin, M., IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell, 2005, 121(7), 977-990.
338. Chen, F.; Castranova, V., Nuclear factor-kappaB, an unappreciated tumor suppressor. Cancer Res., 2007, 67(23), 11093-11098.
339. Klein, U.; Ghosh, S., The Two Faces of NF-kappaB Signaling in Cancer Development and Therapy. Cancer Cell, 2011, 20(5), 556-558.
340. Mowla, S. N.; Perkins, N. D.; Jat, P. S., Friend or foe: emerging role of nuclear factor kappa-light-chain-enhancer of activated B cells in cell senescence. Onco. Targets Ther., 2013, 6, 1221-1229.
341. Perkins, N. D., NF-kappaB: tumor promoter or suppressor? Trends Cell Biol., 2004, 14(2), 64-69.
342. Liu, F.; Bardhan, K.; Yang, D.; Thangaraju, M.; Ganapathy, V.; Waller, J. L.; Liles, G. B.; Lee, J. R.; Liu, K., NF-kappaB directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppression. J. Biol. Chem., 2012, 287(30), 25530-25540.
343. Chien, Y.; Scuoppo, C.; Wang, X.; Fang, X.; Balgley, B.; Bolden, J. E.; Premsrirut, P.; Luo, W.; Chicas, A.; Lee, C. S.; Kogan, S. C.; Lowe, S. W., Control of the senescence-associated secretory phenotype by NF-kappaB promotes senescence and enhances chemosensitivity. Genes Dev., 2011, 25(20), 2125-2136.
344. Jing, H.; Kase, J.; Dorr, J. R.; Milanovic, M.; Lenze, D.; Grau, M.; Beuster, G.; Ji, S.; Reimann, M.; Lenz, P.; Hummel, M.; Dorken, B.; Lenz, G.; Scheidereit, C.; Schmitt, C. A.; Lee, S., Opposing roles of NF-kappaB in anti-cancer treatment outcome unveiled by cross-species investigations. Genes Dev., 2011, 25(20), 2137-2146.
345. Chen, Y. J.; Yeh, M. H.; Yu, M. C.; Wei, Y. L.; Chen, W. S.; Chen, J. Y.; Shih, C. Y.; Tu, C. Y.; Chen, C. H.; Hsia, T. C.; Chien, P. H.; Liu, S. H.; Yu, Y. L.; Huang, W. C., Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors. Breast Cancer Res., 2013, 15(6), R108.
346. Klarenbeek, S.; Van Miltenburg, M. H.; Jonkers, J., Genetically engineered mouse models of PI3K signaling in breast cancer. Mol. Oncol., 2013, 7(2), 146-164.
347. Hutti, J. E.; Pfefferle, A. D.; Russell, S. C.; Sircar, M.; Perou, C. M.; Baldwin, A. S., Oncogenic PI3K mutations lead to NF-kappaB-dependent cytokine expression following growth factor deprivation. Cancer Res., 2012, 72(13), 3260-3269.
348. Marczylo, T. H.; Verschoyle, R. D.; Cooke, D. N.; Morazzoni, P.; Steward, W. P.; Gescher, A. J., Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chem. Pharmacol., 2007, 60(2), 171-177.
349. Kanai, M.; Imaizumi, A.; Otsuka, Y.; Sasaki, H.; Hashiguchi, M.; Tsujiko, K.; Matsumoto, S.; Ishiguro, H.; Chiba, T., Doseescalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. Cancer Chem. Pharmacol., 2012, 69(1), 65-70.